[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002224417A1 - Methods for treating il-18 mediated disorders - Google Patents

Methods for treating il-18 mediated disorders

Info

Publication number
AU2002224417A1
AU2002224417A1 AU2002224417A AU2441702A AU2002224417A1 AU 2002224417 A1 AU2002224417 A1 AU 2002224417A1 AU 2002224417 A AU2002224417 A AU 2002224417A AU 2441702 A AU2441702 A AU 2441702A AU 2002224417 A1 AU2002224417 A1 AU 2002224417A1
Authority
AU
Australia
Prior art keywords
treating
methods
mediated disorders
mediated
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224417A
Inventor
Teresa L. Born
Kendall M. Mohler
John E. Sims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2002224417A1 publication Critical patent/AU2002224417A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002224417A 2000-10-18 2001-10-17 Methods for treating il-18 mediated disorders Abandoned AU2002224417A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24140800P 2000-10-18 2000-10-18
US60/241,408 2000-10-18
PCT/US2001/032460 WO2002032374A2 (en) 2000-10-18 2001-10-17 Methods for treating il-18 mediated disorders

Publications (1)

Publication Number Publication Date
AU2002224417A1 true AU2002224417A1 (en) 2002-04-29

Family

ID=22910578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224417A Abandoned AU2002224417A1 (en) 2000-10-18 2001-10-17 Methods for treating il-18 mediated disorders

Country Status (3)

Country Link
US (3) US20020098185A1 (en)
AU (1) AU2002224417A1 (en)
WO (1) WO2002032374A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO2001035974A2 (en) * 1999-11-15 2001-05-25 Pharma Mar S.A. Aplidine treatment of cancers
KR101111103B1 (en) * 2000-02-10 2012-02-13 아보트 러보러터리즈 Antibodies that bind human interleukin-18 and methods of making and using
CN1322897C (en) * 2000-02-21 2007-06-27 应用研究系统Ars股份公司 Use of IL-18 inhibitors
US6899869B2 (en) * 2000-04-25 2005-05-31 Tomoaki Hoshino Method of preparing an animal model for interstitial pneumonia
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7507766B2 (en) * 2000-10-12 2009-03-24 Pharma Mar, S.A. Treatment of cancers
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ME00549B (en) * 2001-01-29 2011-10-10 Serono Lab Use of il-18 inhibitors for the treatment and/or prevention of heart disease
ES2334773T3 (en) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. USE OF IL-18 INHIBITORS FOR THE TREATMENT OR PREVENTION OF SEPSIS.
CA2445664C (en) * 2001-05-25 2012-03-06 Ares Trading S.A. Use of il-18 inhibitors for treating or preventing cns injuries
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
CA2462642A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
PL207303B1 (en) * 2002-03-22 2010-11-30 Inst Nat Sante Rech Med Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
CA2500577C (en) 2002-10-08 2013-12-17 Charles A. Dinarello The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7445779B2 (en) * 2002-12-31 2008-11-04 Schering Corporation Methods of modulating IFNy production
US20040191172A1 (en) * 2003-01-30 2004-09-30 Tomoaki Hoshino Preventive or therapeutic agents for dermatitis or alopecia, evaluation method of the agents, and transgenic mouse
EP1603584B1 (en) * 2003-03-12 2008-08-27 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
US20080076708A1 (en) * 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
EP1736168A4 (en) * 2004-03-11 2008-07-09 Redox Bioscience Inc Protease inhibitor and preventives or remedies for diseases
US7557084B2 (en) 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
JP5595632B2 (en) * 2004-07-16 2014-09-24 敦生 関山 IL-18 receptor antagonist and pharmaceutical composition comprising said antagonist
AU2011226823B2 (en) * 2004-07-16 2012-09-20 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
ME02746B (en) 2004-10-08 2018-01-20 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
JP5048658B2 (en) 2005-06-03 2012-10-17 メルク セローノ ソシエテ アノニム Use of IL-18BP isoforms for the treatment and / or prevention of neuroinflammatory diseases
CA2635472A1 (en) * 2006-02-22 2007-08-30 University Of Zurich Soluble receptors and methods for treating autoimmune or demyelinating diseases
CA2635445A1 (en) * 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
US8133978B2 (en) 2006-05-25 2012-03-13 Glaxo Group Limited Humanised anti-interleukin-18 antibody
SE532249C2 (en) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab New formulations of IL-18 for the treatment of various inflammatory diseases by vaccination
WO2008150431A1 (en) * 2007-05-29 2008-12-11 Yale University Il- 18 and protein kinase r inhibition for the treatment of copd
CL2008002153A1 (en) 2007-07-24 2009-06-05 Amgen Inc Isolated antibody or antigen-binding fragment thereof that binds to the yl-18 (yl-18r) receptor; encoding nucleic acid molecule; host cell comprising it; pharmaceutical composition; medical use to treat or prevent a condition associated with il-18r; In vitro method to inhibit the binding of yl-18 to yl-18r.
US20110150871A1 (en) * 2008-08-18 2011-06-23 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
US20120308564A1 (en) * 2010-02-09 2012-12-06 Andrew Ian Bayliffe Treatment of a metabolic disorder
BR112013008501A2 (en) * 2010-10-08 2016-08-16 Novartis Ag Methods for treating psoriasis using il-17 anatgonists
JOP20200308A1 (en) 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules
SG11201601717VA (en) 2013-09-05 2016-04-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
RU2755691C2 (en) 2015-03-05 2021-09-20 Аб2 Био Са Il-18-binding protein (il-18bp) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
WO2019213686A1 (en) * 2018-05-10 2019-11-14 The Council Of The Queensland Institute Of Medical Research Therapeutic compositions and uses therefor
WO2020163715A1 (en) * 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting il18r1
CA3191161A1 (en) 2020-08-14 2022-02-17 Kite Pharma, Inc Improving immune cell function
WO2023286694A1 (en) * 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 Medicinal composition for treating inflammatory bowel disease
WO2023220560A1 (en) * 2022-05-09 2023-11-16 Minerva Biotechnologies Corporation Chimeric antigen receptor and il-18 receptor compositions and methods of use therein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DK0628639T3 (en) * 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Reconstituted human antibody to human interleukin-6 receptor
EP0692536B1 (en) * 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
EP0816499A3 (en) * 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP2001522357A (en) * 1997-04-24 2001-11-13 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted imidazoles useful for treating inflammatory diseases
AR022952A1 (en) * 1999-03-19 2002-09-04 Smithkline Beecham Corp MONOCLONAL ANTIBODY OF ROEDOR SPECIFICALLY NEUTRALIZING FOR HUMAN INTERLEUQUINE-18, A FAB NEUTRALIZING FRAGMENT OR FRAGMENT F (AB ') 2, A COMPLEMENTARITY REGION OF IMMONOGLOBULIN LIGHT CHAIN (CDR), WHICH MAKES IT COMPRESSED , THE
US6497870B1 (en) * 2000-05-22 2002-12-24 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist

Also Published As

Publication number Publication date
US20090297517A1 (en) 2009-12-03
WO2002032374A2 (en) 2002-04-25
US20080213257A1 (en) 2008-09-04
WO2002032374A3 (en) 2002-09-19
US20020098185A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2002224417A1 (en) Methods for treating il-18 mediated disorders
AU2001285159A1 (en) Methods for treating endocrine disorders
AU7085100A (en) Method for treating otic disorders
AU2001231223A1 (en) Therapeutic method for reducing angiogenesis
AU2001269799A1 (en) Methods for treating various eye disorders
AU2001288271A1 (en) Methods for treating inflammatory diseases
AU2002215125A1 (en) Well treatment method
AU2001227966A1 (en) Methods for treating tumors
AU2001252605A1 (en) Laser treatment apparatus
AU8298801A (en) Methods for treating atopic disorders
AU2002240401A1 (en) Methods and apparatus for treating hemorrhoids and similar ailments
AU2001267212A1 (en) Ozonation process
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU2001237939A1 (en) Methods for treating glaucoma
AU2001275209A1 (en) Power steering apparatus
AU2002308642A1 (en) Methods for treating cancer
AU2002214487A1 (en) Method for inducing apoptiosis
AU2002326991A1 (en) Methods for treating multiple sclerosis
AU2001295036A1 (en) Apparatus for performing microcurrentelectrotherapy
AU2001290122A1 (en) Audio apparatus
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2001261324A1 (en) Psoriasis treatment
AU2002356482A1 (en) Strewing apparatus
AUPR964901A0 (en) Waste treatment apparatus